Medication info

Terbinafine Tablets (Terbinafine Hydrochloride)

Prescription medicationTabletApproval withdrawn
Ingredient · strength
Terbinafine Hydrochloride›140.625mg / 1 tablet
Manufacturer / importer
HLB Pharma Co., Ltd.
Appearance
White to almost beige round tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 200101878 · Notified 2001.12.01

This product's status changed to Approval withdrawn on 2024.04.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of onychomycosis, dermatomycosis (including tinea pedis and tinea corporis), and tinea capitis
Who uses it
Adults · Children
Adult dosage
Administer terbinafine 125 mg twice daily or 250 mg once daily. The duration of treatment according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Treatment is usually given for 6 weeks~3 months. For infections of the fingernails or relatively small toenails, or in younger patients, the treatment duration may be shortened to 3 months or less. Three months is usually sufficient to treat toenail infections, but treatment may take 6 months or longer in some patients. Treatment may take longer in patients with slow nail growth. 3. Patients with renal impairment For patients with creatinine clearance below 50 mL/min, reduce the daily dose by 1/2.
Children's dosage
Administer to children aged 2 years and older. There is no experience with administration in children under 2 years of age; therefore, use is not recommended. Tinea capitis: 4 weeks Tinea capitis occurs primarily in children. To prevent recurrence of infection, treatment should be given regularly for the appropriate prescribed duration. Body weight below 20 kg (under 5 years): Administer 62.5 mg once daily. As experience with administration is limited, the decision to administer should be based on consideration of the benefits and risks of treatment. Body weight 20~40 kg (5~12 years): Administer 125 mg once daily. Body weight over 40 kg (over 12 years): Administer 250 mg once daily.

Ingredients

Manufacturer
HLB Pharma Co., Ltd.

Efficacy & effects

Treatment of onychomycosis, dermatomycosis (including tinea pedis and tinea corporis), and tinea capitis

  • Skin fungal infections
  • tinea pedis
  • tinea corporis
  • tinea cruris
  • onychomycosis
  • tinea capitis
View approved original text

This medication is used in adults for tinea pedis, tinea corporis, tinea cruris, and onychomycosis caused by dermatophytes, and in children for tinea capitis.

Dosage and Administration

Adult dosage

Administer terbinafine 125 mg twice daily or 250 mg once daily. The duration of treatment according to the condition is as follows. 1) Dermatophytosis Tinea pedis (interdigital, plantar/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Treatment is usually given for 6 weeks~3 months. For infections of the fingernails or relatively small toenails, or in younger patients, the treatment duration may be shortened to 3 months or less. Three months is usually sufficient to treat toenail infections, but treatment may take 6 months or longer in some patients. Treatment may take longer in patients with slow nail growth. 3. Patients with renal impairment For patients with creatinine clearance below 50 mL/min, reduce the daily dose by 1/2.

Children's dosage

Administer to children aged 2 years and older. There is no experience with administration in children under 2 years of age; therefore, use is not recommended. Tinea capitis: 4 weeks Tinea capitis occurs primarily in children. To prevent recurrence of infection, treatment should be given regularly for the appropriate prescribed duration. Body weight below 20 kg (under 5 years): Administer 62.5 mg once daily. As experience with administration is limited, the decision to administer should be based on consideration of the benefits and risks of treatment. Body weight 20~40 kg (5~12 years): Administer 125 mg once daily. Body weight over 40 kg (over 12 years): Administer 250 mg once daily.

Precautions

This medication is not recommended for patients with chronic liver disease or active liver disease. Before taking this medication, liver disease must be confirmed, and regular liver function tests should be performed. Symptoms of liver dysfunction include nausea, loss of appetite, fatigue, vomiting, upper right abdominal pain, jaundice, dark urine, and loose stools, and if any of these symptoms occur, the doctor must be notified immediately. If liver dysfunction is suspected while taking this medication, usage should be discontinued immediately and tests should be conducted. Patients with blood disorders, severely impaired kidney function, children under 2 years of age, and nursing women should avoid this medication. Additionally, if there is an allergy to this medication or its components, use should be avoided. Elderly patients, underweight children, and patients with impaired kidney function should use this medication with extra caution, and if severe rashes or allergic reactions occur, usage should be discontinued immediately. This medication can affect liver function, so it is important to receive monthly liver function tests during the first two months of treatment. Symptoms such as muscle pain, joint pain, headache, taste disturbances, indigestion, and dizziness may occur, and if symptoms worsen, consulting a doctor is advised. This medication can interact with other medications, so it is essential to inform the doctor or pharmacist of any medications being taken. Particularly, dosage adjustments may be needed when taken with medications metabolized in the liver. Women who are pregnant or could become pregnant should carefully consider the benefits and risks of using this medication, and nursing mothers should ideally discontinue breastfeeding while using it. This medication should be stored out of reach of children, away from direct sunlight, and at room temperature. In cases of overdose, symptoms such as headache, nausea, abdominal pain, and dizziness may appear, and immediate medical attention is required.

Side effects

Persistent nausea, loss of appetite, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, loose stools, hepatobiliary failure, hepatitis, cholestasis, jaundice, rash, skin itching, fever, nausea, vomiting, anorexia, lethargy, elevated γ-GTP, elevated AST/ALT, elevated LDH, elevated ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, petechiae, leukopenia, anemia, rash, itching, photosensitivity reaction, skin/mucous membrane syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, blistering dermatitis, psoriasis-type rash, exacerbation of psoriasis, hair loss, musculoskeletal reaction, arthralgia, myalgia, weakness, elevated CPK, increased serum myoglobin, increased urinary myoglobin, hypotension, dyspnea, chest tightness, urticaria, erythema, facial edema, lymphangiectasia, abdominal distension, dyspepsia, mild abdominal pain, diarrhea, discomfort in the upper abdomen, thirst, glossitis, depression, anxiety, headache, taste disturbance, dizziness, drowsiness, sensory abnormalities, sensory loss, decreased attention, insomnia, elevated BUN, increased urinary frequency, visual impairment, tinnitus, anaphylactic reaction, angioedema, systemic lupus erythematosus, elevated total blood cholesterol, increased triglycerides, lethargy, tongue discoloration, palpitations, edema, menstrual irregularities, paralysis, systemic disorders, fever, fatigue, weight loss, anaphylactic reaction, serum sickness-like reaction, blurred vision, decreased vision, hearing loss, auditory impairment, vasculitis, permanent loss of smell, hyposmia, drug rash, pancreatitis, rhabdomyolysis, influenza-like illness, increased blood creatine phosphokinase, headache, nausea, upper abdominal pain, dizziness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering, and it is safe to store at room temperature between 1 degree and 30 degrees Celsius. Storing it this way can help maintain the medication’s effectiveness.

Appearance and packaging

Appearance

White to almost beige round tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.